Biogen (BIIB) Sees Boost Following Early FDA Approval of Leqembi
Related Stocks: BIIB
Read the full article3d agoen
You might also wanna read
Biogen (BIIB) Stock Jumps on Analyst Upgrade Before Key Alzheimer’s Data Release
Truist upgrades Biogen (BIIB) stock to Buy with $235 target ahead of Alzheimer's drug data. Shares rise 1.3% premarket on positive analyst o
Blockonomi·3d ago
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
This could be a key move for future growth.
Bars·12d ago
STAT+: Akero team, backed by Fairmount, launches new immunology company
FDA approves injectable Leqembi, another post-Makary reversal, and other biotech news from The Readout
STAT·2d ago
New drug data could lift shares of this biotechnology stock, Truist says
Biogen could see more upside if it publishes positive results from recent trials linked to kidney and Alzheimer's treatments, Truist Securit
cnbc.com·3d agoNew drug data could lift shares of this biotechnology stock, Truist says
Biogen could see more upside if it publishes positive results from recent trials linked to kidney and Alzheimer's treatments, ...
cnbc.com·3d ago
Q32 Bio stock soared after its alopecia drug cleared a key clinical bar
The biotech's Phase 2a study of bempikibart showed a 35.3% mean reduction in hair loss scores, with the company planning a registration-dire
Quartz·2d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.